ViiV Healthcare clinical trials

A subsidiary of GlaxoSmithKline

The registry lists 265 studies whose lead sponsor is ViiV Healthcare. 16 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 265. List all 265 → · All GlaxoSmithKline studies →

• A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult ParticipantsRecruitingNCT07818915Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedRecruitingNCT07650916Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIVNot yet recruitingNCT07822477Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)Not yet recruitingNCT07816250Phase 2

  Sponsor listed in the registry: ViiV Healthcare

• A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentRecruitingNCT07393659Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• First Time in Human Study of Long Acting VH4524184 FormulationsRecruitingNCT06310551Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)RecruitingNCT07202546Phase 2

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate the Safety and PK of VH4770359 in Healthy ParticipantsRecruitingNCT07525544Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184RecruitingNCT07636928Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1RecruitingNCT07275606Phase 1/2

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsRecruitingNCT05418868Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIVRecruitingNCT06724640Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)AvailableNCT04233047

  Sponsor listed in the registry: ViiV Healthcare

• Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in PediatricsRecruitingNCT05674656Phase 1/2

  Sponsor listed in the registry: ViiV Healthcare

• Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant WomenRecruitingNCT03564613

  Sponsor listed in the registry: ViiV Healthcare

• GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIVAvailableNCT03462810

  Sponsor listed in the registry: ViiV Healthcare

• Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsActive, not recruitingNCT03299049Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIVTerminatedNCT06652958Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyActive, not recruitingNCT05979311Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)Active, not recruitingNCT06741397Phase 2

  Sponsor listed in the registry: ViiV Healthcare

• A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE TerritoriesCompletedNCT05514509Phase 4

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1Active, not recruitingNCT06694805Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVActive, not recruitingNCT07053384Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsActive, not recruitingNCT02362503Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy AdultsCompletedNCT06012136Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsActive, not recruitingNCT02938520Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)Active, not recruitingNCT06134362Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)Active, not recruitingNCT05996471Phase 2

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAFCompletedNCT05911360Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsActive, not recruitingNCT02951052Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult ParticipantsCompletedNCT04484337Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral TherapyCompletedNCT05917509Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy AdultsCompletedNCT07066722Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult ParticipantsCompletedNCT06033547Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019CompletedNCT03016533Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) ActivityCompletedNCT05631704Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United StatesCompletedNCT05374525Phase 4

  Sponsor listed in the registry: ViiV Healthcare

• Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected AdolescentsCompletedNCT03682848Phase 3

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIVActive, not recruitingNCT06970223Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1TerminatedNCT06061081Phase 2

  Sponsor listed in the registry: ViiV Healthcare

• Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected AdultsCompletedNCT06039579Phase 2

  Sponsor listed in the registry: ViiV Healthcare

• Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in GermanyCompletedNCT03754803

  Sponsor listed in the registry: ViiV Healthcare

• First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy ParticipantsCompletedNCT05163522Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• GSK3739937 First-Time-In-Human (FTIH) Study in Healthy VolunteersCompletedNCT04493684Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1CompletedNCT06214052Phase 2

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy AdultsActive, not recruitingNCT06786520Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)WithdrawnNCT06533280Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy ParticipantsCompletedNCT05393271Phase 1

  Sponsor listed in the registry: ViiV Healthcare

• Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)CompletedNCT04982445Phase 4

  Sponsor listed in the registry: ViiV Healthcare

• A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy ParticipantsCompletedNCT06368986Phase 1

  Sponsor listed in the registry: ViiV Healthcare